MAP2K7 and neurofibromatosis type 1: Mirdametinib is an orally bioavailable MEK inhibitor that has recently achieved its first regulatory approval in the United States for the treatment of symptomatic, inoperable NF1-associated PNs in both adult and pediatric patients (Table 1) [105].